Calidi Biotherapeutics, Inc. 8-K

What Happened

• Calidi Biotherapeutics, Inc. (CLDI) filed a Form 8-K on Jan 29, 2026 (press release dated Jan 28, 2026) reporting corporate updates for the fiscal year ended December 31, 2025 and providing preliminary, unaudited financial information. The filing includes forward-looking disclosures about the company’s plans and priorities for fiscal 2026.
• Management disclosed that the preliminary financial figures are based on information available as of the press release date and remain subject to completion of closing procedures and the audit of the Company’s FY2025 financial statements. The company also said it plans to submit an Investigational New Drug (IND) application by the end of 2026.

Key Details

• Filing date: Form 8-K filed Jan 29, 2026; press release dated Jan 28, 2026.
• Period covered: Fiscal year ended December 31, 2025; FY2026 operational initiatives outlined.
• Financial status: Preliminary, unaudited FY2025 financial information provided and subject to final closing procedures and audit—results may change materially.
• Development milestone: Company plans to target IND submission by end of 2026 (a stated operational priority).

Why It Matters

• For investors, the 8-K gives an early look at Calidi’s FY2025 results and the company’s near-term clinical development plan; however, the financials are preliminary and could change after the audit, so treat the numbers as provisional.
• The IND submission target is a clear clinical milestone that could affect the company’s valuation if achieved, but timing and success depend on R&D progress, regulatory feedback, funding, and other risks called out in the filing’s forward-looking statements.